J&J's canagliflozin may raise heart risks

01/9/2013 | USA Today · Bloomberg

An FDA panel on Tuesday concluded that Johnson & Johnson's experimental diabetes drug canagliflozin may slightly raise the odds of heart attack, stroke or death as it increased bad cholesterol levels in patients compared with two other diabetes medications. The drug, part of a class known as SGLT2 inhibitors, might help control blood glucose levels in patients with type 2 diabetes, as well as aid in weight loss and lowering blood pressure, a company spokesman said.

View Full Article in:

USA Today · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR